256 related articles for article (PubMed ID: 8824468)
1. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts.
Schmoeckel M; Nollert G; Shahmohammadi M; Young VK; Chavez G; Kasper-König W; White DJ; Müller-Höcker J; Arendt RM; Wilbert-Lampen U; Hammer C; Reichart B
Transplantation; 1996 Sep; 62(6):729-34. PubMed ID: 8824468
[TBL] [Abstract][Full Text] [Related]
2. Transgenic human decay accelerating factor makes normal pigs function as a concordant species.
Schmoeckel M; Nollert G; Shahmohammadi M; Müller-Höcker J; Young VK; Kasper-König W; White DJ; Hammer C; Reichart B
J Heart Lung Transplant; 1997 Jul; 16(7):758-64. PubMed ID: 9257258
[TBL] [Abstract][Full Text] [Related]
3. Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.
Charreau B; Ménoret S; Tesson L; Azimzadeh A; Audet M; Wolf P; Marquet R; Verbakel C; Ijzermans J; Cowan P; Pearse M; d'Apice A; Soulillou JP; Anegon I
Mol Med; 1999 Sep; 5(9):617-30. PubMed ID: 10551903
[TBL] [Abstract][Full Text] [Related]
4. Soluble Galalpha(1,3)Gal conjugate combined with hDAF preserves morphology and improves function of cardiac xenografts.
Brandl U; Erhardt M; Michel S; Jöckle H; Burdorf L; Bittmann I; Rössle M; Mordstein V; Brenner P; Hammer C; Reichart B; Schmoeckel M
Xenotransplantation; 2007 Jul; 14(4):323-32. PubMed ID: 17669174
[TBL] [Abstract][Full Text] [Related]
5. Combining the hDAF transgene with the GP IIb/IIIa inhibitor tirofiban improves heart performance and reduces myocardial damage following hyperacute rejection in an ex vivo perfusion model.
Brandl U; Erhardt M; Joeckle H; Michel S; Brenner P; Bittmann I; Roessle M; Mordstein V; Hammer C; Schmoeckel M; Reichart B
Transplant Proc; 2005; 37(1):491-2. PubMed ID: 15808686
[TBL] [Abstract][Full Text] [Related]
6. Contrast in the efficacy of hDAF mouse hearts between ex vivo perfusion and transplantation into primates.
Verbakel CA; de Bruin RW; Bonthuis F; Jonker M; Dekker S; Marquet RL; IJzermans JN
Xenotransplantation; 2001 Nov; 8(4):284-91. PubMed ID: 11737854
[TBL] [Abstract][Full Text] [Related]
7. Reduction of hyperacute rejection and protection of metabolism and function in hearts of human decay accelerating factor (hDAF)-expressing pigs.
Smolenski RT; Forni M; Maccherini M; Bacci ML; Slominska EM; Wang H; Fornasari P; Giovannoni R; Simeone F; Zannoni A; Frati G; Suzuki K; Yacoub MH; Lavitrano M
Cardiovasc Res; 2007 Jan; 73(1):143-52. PubMed ID: 17134686
[TBL] [Abstract][Full Text] [Related]
8. HDAF transgenic pig livers are protected from hyperacute rejection during ex vivo perfusion with human blood.
Luo Y; Levy G; Ding J; Qi J; Chakbrati S; Garcia BM; Phillips MJ; Kumar N; Friend P; Noble L; Macdonald J; Zhong R; Grant D
Xenotransplantation; 2002 Jan; 9(1):36-44. PubMed ID: 12005103
[TBL] [Abstract][Full Text] [Related]
9. Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days.
Ramirez P; Chavez R; Majado M; Munitiz V; Muñoz A; Hernandez Q; Palenciano CG; Pino-Chavez G; Loba M; Minguela A; Yelamos J; Gago MR; Vizcaino AS; Asensi H; Cayuela MG; Segura B; Marin F; Rubio A; Fuente T; Robles R; Bueno FS; Sansano T; Acosta F; Rodriguez JM; Navarro F; Cabezuelo J; Cozzi E; White DJ; Calne RY; Parrilla P
Transplantation; 2000 Oct; 70(7):989-98. PubMed ID: 11045632
[TBL] [Abstract][Full Text] [Related]
10. Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay-accelerating factor.
Pascher A; Poehlein C; Storck M; Prestel R; Mueller-Hoecker J; White DJ; Abendroth D; Hammer C
Transplantation; 1997 Aug; 64(3):384-91. PubMed ID: 9275100
[TBL] [Abstract][Full Text] [Related]
11. Reduced fibrin deposition and intravascular thrombosis in hDAF transgenic pig hearts perfused with tirofiban.
Brandl U; Jöckle H; Erhardt M; Michel S; Burdorf L; Brenner P; Bittmann I; Rössle M; Mordstein V; Hammer C; Thein E; Reichart B; Schmoeckel M
Transplantation; 2007 Dec; 84(12):1667-76. PubMed ID: 18165780
[TBL] [Abstract][Full Text] [Related]
12. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion.
McCurry KR; Kooyman DL; Diamond LE; Byrne GW; Logan JS; Platt JL
Transplantation; 1995 Apr; 59(8):1177-82. PubMed ID: 7537395
[TBL] [Abstract][Full Text] [Related]
13. The contribution of endothelial cells to hyperacute rejection in xenogeneic perfused working hearts.
Suckfüll MM; Pieske O; Müdsam M; Babic R; Hammer C
Transplantation; 1994 Jan; 57(2):262-7. PubMed ID: 8310518
[TBL] [Abstract][Full Text] [Related]
14. Transgenic expression in pig hearts of both human decay-accelerating factor and human membrane cofactor protein does not provide an additional benefit to that of human decay-accelerating factor alone in pig-to-baboon xenotransplantation.
Mañez R; Lopez-Pelaez E; Centeno A; Herrera JM; Juffe A; Domenech N; Harrison R; Schuurman HJ
Transplantation; 2004 Sep; 78(6):930-3. PubMed ID: 15385816
[TBL] [Abstract][Full Text] [Related]
15. Multiple genetically modified GTKO/hCD46/HLA-E/hβ2-mg porcine hearts are protected from complement activation and natural killer cell infiltration during ex vivo perfusion with human blood.
Abicht JM; Sfriso R; Reichart B; Längin M; Gahle K; Puga Yung GL; Seebach JD; Rieben R; Ayares D; Wolf E; Klymiuk N; Baehr A; Kind A; Mayr T; Bauer A
Xenotransplantation; 2018 Sep; 25(5):e12390. PubMed ID: 29536572
[TBL] [Abstract][Full Text] [Related]
16. Human CD55 expression blocks hyperacute rejection and restricts complement activation in Gal knockout cardiac xenografts.
McGregor CG; Ricci D; Miyagi N; Stalboerger PG; Du Z; Oehler EA; Tazelaar HD; Byrne GW
Transplantation; 2012 Apr; 93(7):686-92. PubMed ID: 22391577
[TBL] [Abstract][Full Text] [Related]
17. The function of transgenic human DAF-expressing porcine livers during hemoperfusion with human blood.
Pöhlein C; Pascher A; Storck M; Young VK; König W; Abendroth D; Wick M; Thiery J; White DJ; Hammer C
Transpl Int; 1996; 9 Suppl 1():S392-6. PubMed ID: 8959871
[TBL] [Abstract][Full Text] [Related]
18. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors.
Zaidi A; Schmoeckel M; Bhatti F; Waterworth P; Tolan M; Cozzi E; Chavez G; Langford G; Thiru S; Wallwork J; White D; Friend P
Transplantation; 1998 Jun; 65(12):1584-90. PubMed ID: 9665074
[TBL] [Abstract][Full Text] [Related]
19. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
[TBL] [Abstract][Full Text] [Related]
20. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model.
Kroshus TJ; Bolman RM; Dalmasso AP; Rollins SA; Guilmette ER; Williams BL; Squinto SP; Fodor WL
Transplantation; 1996 May; 61(10):1513-21. PubMed ID: 8633381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
